These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 29600505)

  • 41. Cost-effectiveness analysis of insulin degludec compared with insulin glargine u100 for the management of type 1 and type 2 diabetes mellitus - from the Spanish National Health System perspective.
    Mezquita-Raya P; Darbà J; Ascanio M; Ramírez de Arellano A
    Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):587-595. PubMed ID: 28649881
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Economic burden of hypoglycemia with basal insulin in type 2 diabetes.
    Fonseca V; Chou E; Chung HW; Gerrits C
    Am J Manag Care; 2017 Feb; 23(2):114-122. PubMed ID: 28245655
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hospitalization Costs Due to Hypoglycemia in Patients with Diabetes: A Microcosting Approach.
    Ferreira JP; Araújo F; Dores J; Santos L; Pape E; Reis M; Chipepo Á; Nascimento E; Baptista A; Pires V; Marques C; Lages AS; Conceição J; Laires PA; Pelicano-Romano J; Alão S
    Diabetes Ther; 2020 Oct; 11(10):2237-2255. PubMed ID: 32654070
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria.
    Russel-Szymczyk M; Valov V; Savova A; Manova M
    BMC Endocr Disord; 2019 Dec; 19(1):132. PubMed ID: 31796048
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An international survey on hypoglycemia among insulin-treated type I and type II diabetes patients: Turkey cohort of the non-interventional IO HAT study.
    Emral R; Tetiker T; Sahin I; Sari R; Kaya A; Yetkin İ; Cil SU; Tütüncü NB;
    BMC Endocr Disord; 2018 Feb; 18(1):9. PubMed ID: 29433560
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pan-European Economic Analysis to Identify Cost Savings for the Health Care Systems as a Result of Integrating Glucose Monitoring Based Telemedical Approaches Into Diabetes Management.
    Fritzen K; Basinska K; Rubio-Almanza M; Nicolucci A; Kennon B; Vergès B; Zakrzewska K; Schnell O
    J Diabetes Sci Technol; 2019 Nov; 13(6):1112-1122. PubMed ID: 30917691
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Healthcare Resource Utilization and Costs Associated with Ketosis Events in Pediatric and Adult Patients with Type 1 Diabetes Mellitus in the UK.
    Thalange N; Aldhouse NVJ; Kitchen H; Howard D; Tutkunkardas D; Håkan-Bloch J
    Diabetes Ther; 2017 Oct; 8(5):1065-1078. PubMed ID: 28905317
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost of Severe Hypoglycemia and Budget Impact with Nasal Glucagon in Patients with Diabetes in Spain.
    Osumili B; Artime E; Mitchell B; Rubio-de Santos M; Díaz-Cerezo S; Giménez M; Spaepen E; Sharland H; Valentine WJ
    Diabetes Ther; 2022 Apr; 13(4):775-794. PubMed ID: 35297026
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark.
    Pollock RF; Tikkanen CK
    J Med Econ; 2017 Mar; 20(3):213-220. PubMed ID: 27705031
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost effectiveness of self-monitoring of blood glucose (SMBG) for patients with type 2 diabetes and not on insulin: impact of modelling assumptions on recent Canadian findings.
    Tunis SL
    Appl Health Econ Health Policy; 2011 Nov; 9(6):351-65. PubMed ID: 21892840
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Insulin degludec versus insulin glargine U100 for patients with type 1 or type 2 diabetes in the US: a budget impact analysis with rebate tables.
    Lane WS; Weatherall J; Gundgaard J; Pollock RF
    J Med Econ; 2018 Feb; 21(2):144-151. PubMed ID: 28945173
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Medical resource use, disturbance of daily life and burden of hypoglycemia in insulin-treated patients with diabetes: results from a European online survey.
    Willis WD; Diago-Cabezudo JI; Madec-Hily A; Aslam A
    Expert Rev Pharmacoecon Outcomes Res; 2013 Feb; 13(1):123-30. PubMed ID: 23402452
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Budget impact analysis of continuous glucose monitoring in individuals with type 2 diabetes on insulin treatment in England.
    Alsaif M; Farhat A; Blumer Z; Barham L
    Health Econ Rev; 2024 May; 14(1):32. PubMed ID: 38709338
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Incidence of Hypoglycemia among Insulin-Treated Patients with Type 1 or Type 2 Diabetes: Bangladeshi Cohort of International Operations-Hypoglycemia Assessment Tool Study.
    Pathan MF; Fariduddin M; Nazimuddin K; Mollah AS; Islam Siddiqui MN; Hassan KA; Ferdous HS; Rahman MH; Ashrafuzzaman SM; Sobhan MJ; E-Tanvir Haider MR; Amin MF
    Indian J Endocrinol Metab; 2018; 22(3):379-386. PubMed ID: 30090731
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost of hospital treatment of type 1 diabetes (T1DM) and type 2 diabetes (T2DM) compared to the non-diabetes population: a detailed economic evaluation.
    Stedman M; Lunt M; Davies M; Livingston M; Duff C; Fryer A; Anderson SG; Gadsby R; Gibson M; Rayman G; Heald A
    BMJ Open; 2020 May; 10(5):e033231. PubMed ID: 32376746
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies.
    Xie L; Wei W; Pan C; Baser O
    J Med Econ; 2013 Sep; 16(9):1137-45. PubMed ID: 23859434
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden.
    Ericsson Å; Pollock RF; Hunt B; Valentine WJ
    J Med Econ; 2013 Dec; 16(12):1442-52. PubMed ID: 24147661
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nasal Glucagon Versus Injectable Glucagon for Severe Hypoglycemia: A Cost-Offset and Budget Impact Analysis.
    Pöhlmann J; Mitchell BD; Bajpai S; Osumili B; Valentine WJ
    J Diabetes Sci Technol; 2019 Sep; 13(5):910-918. PubMed ID: 30700165
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The cost-effectiveness and budget impact of stepwise addition of bolus insulin in the treatment of type 2 diabetes: evaluation of the FullSTEP trial.
    Saunders R; Lian J; Karolicki B; Valentine W
    J Med Econ; 2014 Dec; 17(12):827-36. PubMed ID: 25168164
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Economic burden of hypoglycemia for type II diabetes mellitus patients in Malaysia.
    Aljunid SM; Aung YN; Ismail A; Abdul Rashid SAZ; Nur AM; Cheah J; Matzen P
    PLoS One; 2019; 14(10):e0211248. PubMed ID: 31652253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.